Minimum length requirement of the alignment domain of human telomerase RNA to sustain catalytic activity in vitro
about
Epigallocatechin Gallate Nanodelivery Systems for Cancer TherapyHuman telomerase RNA template sequence is a determinant of telomere repeat extension rate.Analysis of human telomerase activity and function by two color single molecule coincidence fluorescence spectroscopy.Human MLH1 suppresses the insertion of telomeric sequences at intra-chromosomal sites in telomerase-expressing cells.A novel motif in telomerase reverse transcriptase regulates telomere repeat addition rate and processivity.Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations.Analysis of a long-range interaction between conserved domains of human telomerase RNA.Identification of telomerase RNAs from filamentous fungi reveals conservation with vertebrates and yeasts.G-quadruplex formation at the 3' end of telomere DNA inhibits its extension by telomerase, polymerase and unwinding by helicase.Abrogation of Age-Induced MicroRNA-195 Rejuvenates the Senescent Mesenchymal Stem Cells by Reactivating Telomerase.Structure-function relationship and biogenesis regulation of the human telomerase holoenzyme.Identification of a new RNA.RNA interaction site for human telomerase RNA (hTR): structural implications for hTR accumulation and a dyskeratosis congenita point mutation.The C terminus of the human telomerase reverse transcriptase is a determinant of enzyme processivity.Structural features of mouse telomerase RNA are responsible for the lower activity of mouse telomerase versus human telomerase.Functional organization of repeat addition processivity and DNA synthesis determinants in the human telomerase multimer.Structural analysis of the catalytic core of human telomerase RNA by FRET and molecular modeling.Processive utilization of the human telomerase template: lack of a requirement for template switching.Direct observation of nucleic acid binding dynamics by the telomerase essential N-terminal domain.
P2860
Q26746909-4EF54D25-5D81-4C4F-8B5F-4A0CF98AB98CQ33220837-B9473E2B-3CAB-4D67-A66C-6A452569415AQ33239614-11A5CC62-1A42-4F82-BFB9-B438B514DE40Q33554104-1F0A63ED-C687-4442-97E9-7CABC11CD755Q33760292-96F03ADB-2903-479D-A33A-2AA9AFAE3BECQ33943465-D92F26A0-1112-44CB-941A-27E900575A14Q34365513-D208A26A-7FDD-400B-BD05-6E178D39191FQ34650480-1E43306A-A831-46C3-A30E-290E15BB5B7AQ35153446-6AA1C9CE-236A-46F2-AB3E-A9B2B683296BQ36701920-3491E829-F209-4872-B303-0A5E1D00216EQ38095606-BEDE0A13-C186-4290-A72E-F6424C85ED09Q38348375-490FF62E-6901-4296-A8DE-EFB65BCBCB52Q39792077-863C6BE8-CABA-4643-AC91-52FEC36E8A7AQ40284536-DCB29404-81C5-4B72-A65B-D7D0320FD369Q40763366-E7490B14-82A0-42DA-A3CB-888910DAA58BQ42947829-E13135F3-7EF8-4E9B-BBF3-F6FD3A05438FQ46109951-A0F096D2-B0CD-4734-ABF7-5ED99E1C5FEBQ52374157-AEBA236F-BB5D-4E61-A4EE-84562A944438
P2860
Minimum length requirement of the alignment domain of human telomerase RNA to sustain catalytic activity in vitro
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Minimum length requirement of ...... in catalytic activity in vitro
@ast
Minimum length requirement of ...... in catalytic activity in vitro
@en
Minimum length requirement of ...... in catalytic activity in vitro
@nl
type
label
Minimum length requirement of ...... in catalytic activity in vitro
@ast
Minimum length requirement of ...... in catalytic activity in vitro
@en
Minimum length requirement of ...... in catalytic activity in vitro
@nl
prefLabel
Minimum length requirement of ...... in catalytic activity in vitro
@ast
Minimum length requirement of ...... in catalytic activity in vitro
@en
Minimum length requirement of ...... in catalytic activity in vitro
@nl
P2093
P2860
P3181
P356
P1476
Minimum length requirement of ...... in catalytic activity in vitro
@en
P2093
Gérald Gavory
Mark Farrow
Shankar Balasubramanian
P2860
P304
P3181
P356
10.1093/NAR/GKF575
P407
P577
2002-10-01T00:00:00Z